高血压治疗中的钙拮抗剂：异质性何时重要。 - Suppr

Suppr

超能文献

Calcium Antagonists in Hypertension Treatment: When Heterogeneity is Important.

作者信息

Sanchez Ramiro, Grassi Guido

机构信息

University Hospital Fundación Favaloro, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina.

Department of Medicine and Surgery, University of Milano-Bicocca, Milano, Italy.

出版信息

Curr Hypertens Rev. 2025;21(2):129-130. doi: 10.2174/0115734021388726250429102020.

DOI:10.2174/0115734021388726250429102020

PMID:40304328

Abstract

摘要

相似文献

Calcium Antagonists in Hypertension Treatment: When Heterogeneity is Important.

Curr Hypertens Rev. 2025;21(2):129-130. doi: 10.2174/0115734021388726250429102020.

Pharmacological interventions for hypertension in children.

Evid Based Child Health. 2014 Sep;9(3):498-580. doi: 10.1002/ebch.1974.

Cochrane in context: pharmacological interventions for hypertension in children.

Evid Based Child Health. 2014 Sep;9(3):581-3. doi: 10.1002/ebch.1975.

Pharmacological interventions for hypertension in children.

Cochrane Database Syst Rev. 2014 Feb 1;2014(2):CD008117. doi: 10.1002/14651858.CD008117.pub2.

Beta-blockers for hypertension.

Cochrane Database Syst Rev. 2007 Jan 24(1):CD002003. doi: 10.1002/14651858.CD002003.pub2.

Calcium channel blockers versus other classes of drugs for hypertension.

Cochrane Database Syst Rev. 2021 Oct 17;10(10):CD003654. doi: 10.1002/14651858.CD003654.pub5.

Calcium channel blockers versus other classes of drugs for hypertension.

Cochrane Database Syst Rev. 2022 Jan 9;1(1):CD003654. doi: 10.1002/14651858.CD003654.pub6.

First-line drugs for hypertension.

Cochrane Database Syst Rev. 2018 Apr 18;4(4):CD001841. doi: 10.1002/14651858.CD001841.pub3.

First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension.

Cochrane Database Syst Rev. 2015 Jan 11;1:CD008170. doi: 10.1002/14651858.CD008170.pub2.

A Systematic Review on the Efficacy of Amlodipine in the Treatment of Patients With Hypertension With Concomitant Diabetes Mellitus and/or Renal Dysfunction, When Compared With Other Classes of Antihypertensive Medication.

Am J Ther. 2015 Sep-Oct;22(5):322-41. doi: 10.1097/MJT.0000000000000202.

本文引用的文献

Efficacy and Safety of Dihydropyridine Calcium Channel Blockers for Primary Hypertension: A Bayesian Network Meta-analysis.

Curr Hypertens Rev. 2025;21(2):117-128. doi: 10.2174/0115734021357729250214090452.

Highlights from the New European Society of Hypertension Guidelines Document.

Curr Hypertens Rev. 2024;20(2):66-69. doi: 10.2174/0115734021309169240508110407.

Sympathetic modulation as a goal of antihypertensive treatment: from drugs to devices.

J Hypertens. 2023 Nov 1;41(11):1688-1695. doi: 10.1097/HJH.0000000000003538. Epub 2023 Sep 4.

Target Blood Pressure and Combination Therapy: Focus on Angiotensin Receptor Blockers Combination with Either Calcium Channel Blockers or Beta Blockers.

Curr Hypertens Rev. 2022;18(2):138-144. doi: 10.2174/1573402118666220627120254.

Calcium channel blockers versus other classes of drugs for hypertension.

Cochrane Database Syst Rev. 2022 Jan 9;1(1):CD003654. doi: 10.1002/14651858.CD003654.pub6.

Two-Drug Combinations as First-Step Antihypertensive Treatment.

Circ Res. 2019 Mar 29;124(7):1113-1123. doi: 10.1161/CIRCRESAHA.118.313294.

Hypertension.

Nat Rev Dis Primers. 2018 Mar 22;4:18014. doi: 10.1038/nrdp.2018.14.

Clinical science of calcium channel blocker to inhibit hypertensive vascular injury.

Curr Hypertens Rev. 2013 Aug;9(3):193-201. doi: 10.2174/1573402110666140131161947.

New Generation Calcium Channel Blockers in Hypertensive Treatment.

Curr Hypertens Rev. 2006 May 1;2(2):103-111. doi: 10.2174/157340206776877370.

Short-versus long-term effects of different dihydropyridines on sympathetic and baroreflex function in hypertension.

Hypertension. 2003 Mar;41(3):558-62. doi: 10.1161/01.HYP.0000058003.27729.5A. Epub 2003 Feb 17.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Calcium Antagonists in Hypertension Treatment: When Heterogeneity is Important.

Curr Hypertens Rev. 2025;21(2):129-130. doi: 10.2174/0115734021388726250429102020.

Pharmacological interventions for hypertension in children.

Evid Based Child Health. 2014 Sep;9(3):498-580. doi: 10.1002/ebch.1974.

Cochrane in context: pharmacological interventions for hypertension in children.

Evid Based Child Health. 2014 Sep;9(3):581-3. doi: 10.1002/ebch.1975.

Pharmacological interventions for hypertension in children.

Cochrane Database Syst Rev. 2014 Feb 1;2014(2):CD008117. doi: 10.1002/14651858.CD008117.pub2.

Beta-blockers for hypertension.

Cochrane Database Syst Rev. 2007 Jan 24(1):CD002003. doi: 10.1002/14651858.CD002003.pub2.

Calcium channel blockers versus other classes of drugs for hypertension.

Cochrane Database Syst Rev. 2021 Oct 17;10(10):CD003654. doi: 10.1002/14651858.CD003654.pub5.

Calcium channel blockers versus other classes of drugs for hypertension.

Cochrane Database Syst Rev. 2022 Jan 9;1(1):CD003654. doi: 10.1002/14651858.CD003654.pub6.

First-line drugs for hypertension.

Cochrane Database Syst Rev. 2018 Apr 18;4(4):CD001841. doi: 10.1002/14651858.CD001841.pub3.

First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension.

Cochrane Database Syst Rev. 2015 Jan 11;1:CD008170. doi: 10.1002/14651858.CD008170.pub2.

Am J Ther. 2015 Sep-Oct;22(5):322-41. doi: 10.1097/MJT.0000000000000202.

本文引用的文献

Efficacy and Safety of Dihydropyridine Calcium Channel Blockers for Primary Hypertension: A Bayesian Network Meta-analysis.

Curr Hypertens Rev. 2025;21(2):117-128. doi: 10.2174/0115734021357729250214090452.

Highlights from the New European Society of Hypertension Guidelines Document.

Curr Hypertens Rev. 2024;20(2):66-69. doi: 10.2174/0115734021309169240508110407.

Sympathetic modulation as a goal of antihypertensive treatment: from drugs to devices.

J Hypertens. 2023 Nov 1;41(11):1688-1695. doi: 10.1097/HJH.0000000000003538. Epub 2023 Sep 4.

Target Blood Pressure and Combination Therapy: Focus on Angiotensin Receptor Blockers Combination with Either Calcium Channel Blockers or Beta Blockers.

Curr Hypertens Rev. 2022;18(2):138-144. doi: 10.2174/1573402118666220627120254.

Calcium channel blockers versus other classes of drugs for hypertension.

Cochrane Database Syst Rev. 2022 Jan 9;1(1):CD003654. doi: 10.1002/14651858.CD003654.pub6.

Two-Drug Combinations as First-Step Antihypertensive Treatment.

Circ Res. 2019 Mar 29;124(7):1113-1123. doi: 10.1161/CIRCRESAHA.118.313294.

Hypertension.

Nat Rev Dis Primers. 2018 Mar 22;4:18014. doi: 10.1038/nrdp.2018.14.

Clinical science of calcium channel blocker to inhibit hypertensive vascular injury.

Curr Hypertens Rev. 2013 Aug;9(3):193-201. doi: 10.2174/1573402110666140131161947.

New Generation Calcium Channel Blockers in Hypertensive Treatment.

Curr Hypertens Rev. 2006 May 1;2(2):103-111. doi: 10.2174/157340206776877370.

Short-versus long-term effects of different dihydropyridines on sympathetic and baroreflex function in hypertension.

Hypertension. 2003 Mar;41(3):558-62. doi: 10.1161/01.HYP.0000058003.27729.5A. Epub 2003 Feb 17.